Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Morrow

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Open Forum Infectious Diseases|July 21, 2021
Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care TestingKelly A Johnson, Xin Niu, David V Glidden, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2017
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed TherapyPeter L Anderson, Albert Y Liu, Jose R Castillo-Mancilla, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 29, 2019
Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral SuppressionNicholas Musinguzi, Jose Castillo-Mancilla, Mary Morrow, et al.
The Journal of Antimicrobial Chemotherapy|February 23, 2022
Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol useKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 19, 2018
Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic SuppressionJose R Castillo-Mancilla, Mary Morrow, Yap Boum, et al.
Open Forum Infectious Diseases|May 22, 2023
Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic SuppressionJose R Castillo-Mancilla, Mary Morrow, Peter W Hunt, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2020
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvirKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
Open Forum Infectious Diseases|July 20, 2023
Food Insecurity Is Associated With Low Tenofovir Diphosphate in Dried Blood Spots in South African Persons With HIVMolly L Hirsh, Jonathan A Edwards, Chad Robichaux, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 18, 2024
Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine-Based Antiretroviral Therapy (QUANTI-TAF)Ryan P Coyle, Mary Morrow, Sarah C Mann, et al.
Plos Medicine|September 9, 2025
Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing studyKenneth K Mugwanya, Matilda Saina, Nelly R Mugo, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Open Forum Infectious Diseases|July 21, 2021
Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care TestingKelly A Johnson, Xin Niu, David V Glidden, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2017
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed TherapyPeter L Anderson, Albert Y Liu, Jose R Castillo-Mancilla, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 29, 2019
Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral SuppressionNicholas Musinguzi, Jose Castillo-Mancilla, Mary Morrow, et al.
The Journal of Antimicrobial Chemotherapy|February 23, 2022
Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol useKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 19, 2018
Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic SuppressionJose R Castillo-Mancilla, Mary Morrow, Yap Boum, et al.
Open Forum Infectious Diseases|May 22, 2023
Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic SuppressionJose R Castillo-Mancilla, Mary Morrow, Peter W Hunt, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2020
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvirKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
Open Forum Infectious Diseases|July 20, 2023
Food Insecurity Is Associated With Low Tenofovir Diphosphate in Dried Blood Spots in South African Persons With HIVMolly L Hirsh, Jonathan A Edwards, Chad Robichaux, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 18, 2024
Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine-Based Antiretroviral Therapy (QUANTI-TAF)Ryan P Coyle, Mary Morrow, Sarah C Mann, et al.
Plos Medicine|September 9, 2025
Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing studyKenneth K Mugwanya, Matilda Saina, Nelly R Mugo, et al.
Pageof 4